3-氨基-5-乙氧基吡啶 | 51468-00-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基-5-乙氧基吡啶
• 英文名称: 5-ethoxy-pyridin-3-ylamine
• 英文别名: 5-ethoxy-[3]pyridylamine；5-Aethoxy-[3]pyridylamin；3-amino-5-ethoxypyridine；3-Amino-5-ethoxy-pyridin；5-Ethoxy-3-amino-pyridin；3-Amino-5-ethoxypyridin；5-ethoxypyridin-3-amine
• CAS: 51468-00-9
• 化学式: C₇H₁₀N₂O
• 分子量: 138.169
• InChiKey: ZIGPHZOGECKLGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-氨基-5-乙氧基吡啶 在 甲醇 、 sodium hydroxide 、 水 、 caesium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氯氧磷 作用下， 以 二苯醚 、 联苯 、 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 、 异丙醇 、 乙腈 为溶剂， 反应 29.08h， 生成
  参考文献：
  名称：

  WO2007/113548

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氯-5-乙氧基吡啶 在 copper(ll) sulfate pentahydrate 、 氨 作用下， 以 水 为溶剂， 反应 16.0h， 以1.3 g的产率得到3-氨基-5-乙氧基吡啶
  参考文献：
  名称：

  Creating an Antibacterial with in Vivo Efficacy: Synthesis and Characterization of Potent Inhibitors of the Bacterial Cell Division Protein FtsZ with Improved Pharmaceutical Properties

  摘要：

  3-Methoxybenzamide (1) is a weak inhibitor of the essential bacterial cell division protein FtsZ. Alkyl derivatives of 1 are potent antistaphylococcal compounds with suboptimal drug-like properties. Exploration of the structure activity relationships of analogues of these inhibitors led to the identification of potent antistaphylococcal compounds with improved pharmaceutical properties.

  DOI：

  10.1021/jm9016366

文献信息

• [EN] VIRAL REPLICATION INHIBITORS<br/>[FR] INHIBITEURS DE REPLICATION VIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2013045516A1

  公开（公告）日：2013-04-04

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，通过使用这些新化合物来预防或治疗动物的病毒感染的方法，以及将这些新化合物用作药物，更好地用于治疗或预防病毒感染，特别是感染RNA病毒，更特别是感染属于黄病毒科的病毒，更特别是感染登革病毒。本发明还涉及这些新化合物的药物组合或混合制剂，用作药物的组合或制剂，更好地用于预防或治疗病毒感染。该发明还涉及这些化合物的制备方法。
• Benzazepine Dicarboxamide Compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160257653A1

  公开（公告）日：2016-09-08

  This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R 1 to R 4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

  这项发明涉及一种新型苯并哒唑二羧酰胺化合物，其化学式如下，其中R1至R4如描述和索赔中定义，以及其药学上可接受的盐。这些化合物是TLR激动剂，因此可能作为治疗癌症、自身免疫疾病、炎症、败血症、过敏、哮喘、移植排斥、移植物抗宿主病、免疫缺陷和传染病等疾病的药物而有用。
• VIRAL REPLICATION INHIBITORS
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

  公开号：US20140213586A1

  公开（公告）日：2014-07-31

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，使用这些新化合物预防或治疗动物的病毒感染的方法，以及这些新化合物的药物用途，更好地用于治疗或预防病毒感染，特别是RNA病毒感染，更特别是属于黄病毒科的病毒感染，更进一步地是登革热病毒感染。本发明还涉及新化合物的药物组成物或复合制剂，以及用于预防或治疗病毒感染的药物组成物或制剂。本发明还涉及化合物的制备方法。
• [EN] TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS<br/>[FR] PYRIMIDINES TRICYCLIQUES UTILISÉES EN TANT QU'INHIBITEURS DE LA KINASE 7 DÉPENDANTE DES CYCLINES (CDK7)
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2022136174A1

  公开（公告）日：2022-06-30

  The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-dependent kinase 7 (CDK7) and to their use in the treatment of diseases, e.g., cancer.

  本发明涉及公式（I）的药物化合物和包含该化合物的药物组合物，涉及制备该化合物的过程以及将该化合物用作细胞周期素依赖性激酶7（CDK7）的抑制剂并用于治疗疾病，例如癌症。
• Viral replication inhibitors
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. Leuven R&D

  公开号：US10550123B2

  公开（公告）日：2020-02-04

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新型化合物、使用这些新型化合物预防或治疗动物病毒感染的方法以及用作药物的所述新型化合物，更优选用作治疗或预防病毒感染的药物，特别是 RNA 病毒感染，更特别是属于黄病毒科的病毒感染，更特别是登革热病毒感染。本发明还涉及新型化合物的药物组合物或组合制剂、用作药物的组合物或制剂，更优选用于预防或治疗病毒感染。本发明还涉及化合物的制备工艺。